The comparative in vivo pharmacological efficacy of MTC and LMT salts (TRx0237: 5–75 mg/kg with oral administration for 3–8 weeks) was assessed in these two novel transgenic tau mouse lines modeling cognitive and motor endophenotypes of AD and FTLD tauopathies [169], namely, impairment in spatial learning (L1) and motor learning (L66), respectively [132]. The gene discussed is MAPT; the disease is Alzheimer disease.